CD8A and pancreatic neoplasm: Given that JQ1 treatment can augment both drug penetration and CD8+ T cell infiltration into PDAC tissues, we evaluated the immunotherapy efficacy of IL12 at a lower dose of 250 μg k−1g in combination with JQ1 in the immunocompetent orthotopic pancreatic cancer mouse model.